The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Background: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion. They have been repeatedly shown to induce modest natriuresis and reduce HbA1c, blood pressure, weight, and albuminuria in patients with type 2 diabetes. However, the effects of these agents on kidney and cardiovascular events have not been extensively studied in patients with type 2 diabetes and established kidney disease. Methods: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial aims to compare the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with diabetes and established kidney disease. CREDENCE is a randomized, double-blind, event-driven, placebo-controlled trial set in in 34 countries with a projected duration of ∼5.5 years and enrolling 4,401 adults with type 2 diabetes, estimated glomerular filtration rate ≥30 to <90 mL/min/1.73 m 2, and albuminuria (urinary albumin:creatinine ratio >300 to ≤5,000 mg/g). The study has 90% power to detect a 20% reduction in the risk of the primary outcome (α = 0.05), the composite of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death. Conclusion: CREDENCE will provide definitive evidence about the effects of canagliflozin on renal (and cardiovascular) outcomes in patients with type 2 diabetes and established kidney disease. Trial Registration: EudraCT number: 2013-004494-28; ClinicalTrials.gov identifier: NCT02065791.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An acute reduction in eGFR occurs with other classes of kidney-protective therapies, such as RAS inhibitors and SGLT2 inhibitors, and has been associated with long-term kidney protection (6,11,31,32).”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“There is substantial overlap between the FLOW population and the populations studied in the dedicated kidney outcome studies with SGLT2is (CREDENCE, DAPA-CKD and EMPA-KIDNEY) [15,30,32]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationWorldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., Díez, J., Hart, R. G., Eckardt, K.-U., Kasiske, B. L., McCullough, P. A., Passman, R. S., et al. (2011) · Kidney International · doi:10.1038/ki.2011.223 · Cited by 922
Self-citationMatsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., Jafar, T., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 903
Astor, B. C., the Chronic Kidney Disease Prognosis Consortium, Matsushita, K., Gansevoort, R. T., van der Velde, M., Woodward, M., Levey, A. S., Jong, P. E. D., & Coresh, J. (2011) · Kidney International · doi:10.1038/ki.2010.550 · Cited by 774
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Self-citationBrenner, B. M., Cooper, M. E., & de Zeeuw, D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00549-9 · Cited by 508
Self-citationEffects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., & Meininger, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3167 · Cited by 454
Self-citationCanagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361
Self-citationDiabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Self-citationIntensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
Self-citationLv, J., Ehteshami, P., Sarnak, M. J., Tighiouart, H., Jun, M., Ninomiya, T., Foote, C., Rodgers, A., Zhang, H., Wang, H., et al. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121468 · Cited by 305
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611290 · Cited by 199
Self-citationOrtola, F. V., Ballermann, B. J., Anderson, S., Mendez, R. E., & Brenner, B. M. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113120 · Cited by 195
Self-citationWorldwide Access to Treatment for End-Stage Kidney Disease: A Systematic Review
Liyanage, T., Ninomiya, T., & Jha, V. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.003 · Cited by 191
Inker, L. A., Heerspink, H. J. L., Mondal, H., Schmid, C. H., Tighiouart, H., Noubary, F., Coresh, J., Greene, T., & Levey, A. S. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.017 · Cited by 163
Self-citationNeal, B., Perkovic, V., Mahaffey, K. W., Fulcher, G., Erondu, N., Desai, M., Shaw, W., Law, G., Walton, M. K., Rosenthal, N., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12924 · Cited by 104
Self-citationRosenthal, N., Meininger, G. E., Ways, K., Polidori, D., Desai, M. G., Qiu, R., Alba, M., Vercruysse, F., Balis, D. A., Shaw, W. C., et al. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12852 · Cited by 102
Self-citationLambers Heerspink, H. J., Weldegiorgis, M., Inker, L. A., Gansevoort, R., Parving, H.-H., Dwyer, J. P., Mondal, H., Coresh, J., Greene, T., Levey, A. S., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.09.016 · Cited by 69
Self-citationHeerspink, H. J. L., Persson, F., Brenner, B. M., Chaturvedi, N., Brunel, P., McMurray, J. J. V., Desai, A. S., Solomon, S. D., Pfeffer, M. A., PARVING, H.-H. D., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00469-6 · Cited by 52
Self-citationQiu, R., Balis, D. A., Xie, J., Davies, M. J., Desai, M. G., & Meininger, G. E. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1271780 · Cited by 31
Self-citationAtrial natriuretic peptide and the kidney.
Ballermann, B. J., & Brenner, B. M. (1987) · PubMed · Cited by 27
Self-citationDesai, M. G., Yavin, Y., Balis, D. A., Sun, D., Xie, J., Canovatchel, W. J., & Rosenthal, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12876 · Cited by 27
Self-citation
Research works printed but not linked: 1
- 3 International Diabetes Federation: IDF Diabetes Atlas, 7th edition. Brussels, Belgium, International Diabetes Federation, 2015.
Cited by
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Metadata
- Authors
- Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Levin, A., Pollock, C., Wheeler, D. C., Xie, J., Zhang, H., Zinman, B., Desai, M., Perkovic, V., & on behalf of the CREDENCE study investigators
- Affiliations
- The University of Sydney (AU)
- Stanford Medicine (US)
- Richard L. Roudebush VA Medical Center (US)
- University of Chicago (US)
- Brigham and Women's Hospital (US)
- Janssen Research & Development (United States) (US)
- University of Utah (US)
- University Medical Center Groningen (NL)
- University of British Columbia (CA)
- University College London (GB)
- Peking University First Hospital (CN)
- Mount Sinai Hospital (CA)
- UNSW Sydney (AU)
- ORCID
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 46
- Issue
- 6
- Pages
- 462-472
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- PMC
- PMC5804835
- OpenAlex
- W2772844083
- Cited by
- 234
- References
- 32
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 15 · 2023: 25 · 2022: 16 · 2021: 27 · 2020: 45 · 2019: 51 · 2018: 40 · 2017: 2
- FWCI
- 33.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- American Journal of Nephrology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, diabetic nephropathy, albuminuria, end-stage renal disease, cardiovascular outcomes, renal outcomes, CREDENCE trial, trial design, baseline characteristics
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.